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Objectives: Adherence to immunosuppressive therapy after kidney transplanta-
tion is crucial to avoid graft rejection and optimise long term patient and graft 
survival. However, patient’s adherence is not always optimal. Our aim was to identify 
reasons for non-adherence and health-related quality of life (HRQoL) dimensions 
affected by immunosuppressant therapy (IT) after kidney transplantation (KT) 
including patient preference of once daily over twice daily immunosuppressive 
regimen. MethOds: A literature review on adherence to immunosuppressant ther-
apy (IT) and impact of IT on HRQoL through the EMBASE database was performed. 
Interviews were conducted with 2 clinical experts to determine key concepts related 
to KT and immunosuppressants. Thirty-six patients in four focus groups were asked 
to cite important concepts related to adherence and impact of IT on HRQoL and rate 
them. Qualitative analysis was conducted to code patient’s responses. Results: 
The results showed that non-adherence was mostly unintentional among the par-
ticipants. The reason for non-adherence included forgetfulness, interference with 
lifestyle, being asleep at the time the medication should be taken, change in routine 
and impact of side effects. The twice daily regimen was more problematic in relation 
to adherence. Overall, participants were of the opinion that a once daily IT regimen 
would help them be more adherent. Also, IT impacts on the HRQoL of the patient 
in a number of ways including: restricting the patients’ lifestyle, causing anxiety or 
impairing the patient’s ability to work. Although the patients happily oblige to the 
necessity of taking IT medication, patients preferred to reduce the burden associ-
ated with medication. cOnclusiOns: This study suggested that patients strongly 
valued adherence to IT medication and saw a change in the regimen from twice 
daily to once daily as one way to improve their adherence to IT. Results also sug-
gested that a once daily regimen could improve patient’s HRQoL.
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Objectives: Although pivotal studies of overactive bladder (OAB) medications 
routinely use micturition frequency (MF) when defining the primary or coprimary 
endpoint, few studies have examined minimal important difference (MID) values 
for this parameter. This study explored MID values for MF using data from a Phase 
IIb study in OAB patients with urge predominant incontinence along with esti-
mates for OAB symptoms of urinary urgency (UU), urgency incontinence (UUI), 
and total incontinence (TI). MethOds: The endpoint was defined as the change 
from baseline to 8 weeks in the number of daily episodes averaged over a diary 
week for each parameter. Anchor- and distribution-based methods using statisti-
cal criteria (e.g. half standard deviation) were used to estimate MID ranges for all 
diary parameters. Anchors were selected as a +1 change score representing slight 
improvement for global assessment questions assessing frequency and control 
over OAB symptoms. Results: The sample included 769 OAB patients with (80.4%) 
and without (19.6%) incontinence. The baseline mean number of micturitions was 
11 and the mean (%) change from baseline representing the MID for MF ranged 
from 1.6-1.8 (14.3-16.4%). For urgency, the baseline and mean (%) change was 7 and 
2.4-2.5 (42.7-47.2%), respectively. For total incontinence, the baseline and mean (%) 
change was 3 and 1.5-1.7 (64.3-76.2%), respectively, with similar values for UUI. 
Distribution-based values were much smaller than those derived using anchor-
based methods. cOnclusiOns: The mean changes representing MID estimates 
for micturition frequency were comparable to those observed for incontinence but 
constituted smaller percent changes given the larger number of baseline micturi-
tions. The MID estimates for MF were smaller than the MID estimates for urgency. As 
MID estimates derived for OAB patients have focused mainly on incontinence, these 
results present useful information for designing studies which routinely include 
change in micturition frequency as the primary endpoint of interest.
PUK28
A SYStEmAtIc REvIEW Of hEAlth-RElAtED QUAlItY Of lIfE ASSESSmENt 
fOR chIlDREN AND ADOlEScENtS WIth chRONIc KIDNEY DISEASE
Thach A.V.1, Jiang S.2, Rascati K.L.1
1The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 2The University of 
Texas at Austin, Austin, TX, USA
Objectives: To evaluate health-related quality of life (HRQoL) assessment in chil-
dren and adolescents with chronic kidney disease (CKD). MethOds: A systematic 
literature search was conducted using PubMed, MEDLINE, PsycINFO, and CINAHL 
from the inception of each database until October 2013. Search terms included 
kidney disease, children (or adolescents), health-related quality of life, and instru-
ment. The following inclusion criteria were applied to the studies: (1) published in 
English, (2) in a peer reviewed journal, (3) about children or adolescents with CKD 
or end-stage renal disease (ESRD), and (4) had one of the following outcomes—
development/validation of a disease-specific HRQoL instrument OR use of HRQoL 
as a primary outcome. A modified minimum data checklist developed by Efficace 
and colleagues was used to evaluate the quality of studies that report HRQoL out-
comes. The consensus-based standards for the selection of health measurement 
instruments (COSMIN) was used to evaluate the methodological quality of studies 
that report on the development or validation of HRQoL instruments. Results: A 
low protein diet is cost effective relative to no-treatment in an Italian setting. 
Further studies should test this model in other countries with different dialysis 
costs and dietary support.
PUK23
ASSESSINg thE lIKElY cOSt-UtIlItY Of AlEmtUzUmAb vERSUS RAbbIt 
ANtI-thYmOctE glObUlIN AS INDUctION thERAPY fOR hIgh-RISK KIDNEY 
tRANSPlANt REcIPIENtS
Tung A, Devine E., Garrison L.
University of Washington, Seattle, WA, USA
Objectives: Induction therapy is administered at the time of kidney transplan-
tation to prevent acute rejections. The agent of choice depends on the degree of 
patient risk for acute rejection. In the US, rabbit anti-thymocyte globulin (rATG) 
is the standard agent administered to high-risk patients. A monoclonal antibody 
approved for use in chronic lymphocytic leukemia—alemtuzumab—has been 
shown in off-label use to be equally safe and efficacious as rATG in these patients. 
Furthermore, alemtuzumab costs less, making it a potentially cost-effective alter-
native. Nevertheless, practitioners have been slow to adopt alemtuzumab as an 
induction agent of choice due to concerns that it may be less effective than rATG 
in improving patient survival in the long-term. The objective of this study is to 
the project the incremental cost-effectiveness ratio (ICER) of alemtuzumab versus 
rATG in high-risk patients. MethOds: A decision-analytic model was constructed 
to model costs and outcomes specific to the first 12 months post-transplantation, 
such as for delayed graft function and acute rejection; long-term (30-year) out-
comes were estimated with a Markov model with outcomes measured in life 
years (LYs) and quality-adjusted life years (QALYs). Clinical probabilities were 
obtained from randomized controlled trials; preference weights from direct patient 
measures in previously published literature; and costs from previously published 
cost-effectiveness studies on kidney transplantation. Results: In the base case, 
alemtuzumab was projected to yield 1.18 LYs and 1.09 QALYs gained when com-
pared with rATG. The estimated ICER of alemtuzumab compared to rATG was 
$5,368 per QALY. Sensitivity analysis revealed that the ICER was most sensitive 
to the transition probabilities to graft loss and death. Despite these variations, 
alemtuzumab was cost-effective across all parameter ranges, with the greatest 
ICER being $21,133. cOnclusiOns: In kidney transplant patients at high risk of 
acute rejection, our model suggests that alemtuzumab is likely to be cost-effective, 
yielding an ICER below often-cited thresholds.
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Objectives: Cost Utility Analysis of Sacral Neuromodulation (SNM) vs. 
botulin toxin type A (BoNTA) in Overactive Bladder (OAB) treatment in 
Colombia. MethOds: Through the adaptation of an HTA Consulting economic 
model and after data transferability analysis, a cost-utility analysis of SNM vs. 
BoNTA 100UI in the treatment of OAB in Colombia was done. The model was 
constructed as a Discrete Event Simulation. The effectiveness data of SNM and 
BoNTA, defined as more than 50% improvement in urinary parameters, was based 
on studies identified in systematic review Jaros 2013 conducted in Polish settings. 
Based in systematic search for health-related quality of life data, one health state 
for treatment success and one for treatment failure were defined, as well as disu-
tility related to treatment. The costs data was obtain from the Colombian Public 
Reimbursement Tariff Manual and from urologist medical group specialized in 
OAB treatment, which also reviewed and adjusted the frequency of resources use. 
A 10 years horizon and a 3% discount rate were used. Deterministic and probabil-
istic sensitive analyses were done. Results: The treatment with SNM obtained 
5.67 QALYs vs. 5.38 QALYs obtained with BoNTA with 0.28 incremental QALYs. 
The total costs were US$27,828 vs. US$28,906, with minus US$1,077 incremental 
Dollars. Because SNM was more effective and less costly, dominates to BoNTA, 
meaning that is cost-saving respect to this. 49.1% of the simulations in the 
Probabilistic Sensitivity analysis were in the NE quadrant, more effective and more 
costly, and 50.9% in the SE quadrant, more effective and less costly than BoNTA, 
and 100% under the threshold of 3 Colombian GDP Per Capita. cOnclusiOns: 
SNM has a higher effectiveness than BoNTA in terms of Quality of Life at a lower 
cost and compared to BoNTA is a cost-saving therapy for the treatment of OAB 
in Colombia.
PUK25
cOSt-UtIlItY ANAlYSIS Of vERY lOW-PROtEIN DIEt, lOW-PROtEIN DIEt AND 
fUll-PROtEIN DIEt IN cKD PAtIENtS IN chINA
Wu J.J., Yang L.
Peking University, Beijing, China
Objectives: The aim of this study was to conduct an economic evaluation to 
compare utility and costs of very low-protein diet, low-protein diet and full-
protein diet in CKD patients in China. MethOds: A cost-utility analysis was 
conducted in a hypothetical population with GFR≤ 25ml/min/1.73m42 in 5 years. 
Based on the literature data, patients’ disease progressions with different diets 
are generated in 5 years. Cost data was collected by medical insurance data-
base and out-patient survey. EQ-5D was used to collect patients’ quality of life 
score. Results: In 5 years, patients with full-protein diet had the highest cost 
of CNY520786.8, followed by patients with low-protein diet (CNY503440.3), and 
patients with very-low-protein diet (CNY475066.7). Patients with very-low-protein 
diet had the highest quality-adjusted life-years(4.329),followed by patients with 
low-protein diet (4.036), and patients with full-protein diet(3.980). cOnclusiOns: 
The protein-restricted diet can delay the time of dialysis and then reduce 
patients’ burden and improve patients’ quality of life. In this way, the very-low-
protein diet is the optimal way.
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Objectives: Both generic and disease-specific measures can be a useful strat-
egy for assessing HRQoL outcomes. This post-hoc analysis evaluated the ability 
of the generic EQ-5D-3L instrument and the OAB-5D disease-specific instrument, 
to assess changes in men with LUTS/BPH who have moderate-to-severe storage 
symptoms and voiding symptoms treated with fixed-dose combination (FDC) of 
solifenacin 6mg + oral controlled absorption system [OCAS™] formulation of tamsu-
losin (TOCAS, 0.4mg), TOCAS monotherapy, or placebo. MethOds: Data were avail-
able from a 12-week clinical trial (NEPTUNE). Patients completed the OAB-5D and 
EQ-5D-3L (including EQ-VAS) instruments. Analyses controlled for relevant patient 
characteristics. Analysis of covariance estimated and compared changes from base-
line at each time point for EQ-5D-3L, EQ-VAS and OAB-5D. Results: Statistically 
significant differences were seen in OAB-5D utilities with TOCAS monotherapy and 
FDC solifenacin 6mg + TOCAS compared with placebo after 4, 8 and 12 weeks in 
the overall population. When patients reporting full-health on EQ-5D-3L at baseline 
were excluded from the analysis to reduce the ceiling effect, the improvement 
from baseline (Δ 0.101 for FDC solifenacin + TOCAS) with EQ-5D-3L was 1.5 fold 
greater than the minimally important difference of 0.074. cOnclusiOns: This 
analysis indicates EQ-5D-3L captures several improvements in HRQoL resulting 
from treatment of LUTS/BPH with FDC solifenacin 6mg + TOCAS. However, OAB-5D 
shows larger and more consistent statistically significant differences between pla-
cebo and the treatment arms, and could be considered an appropriate alternative 
to EQ-5D utilities in health economic modelling.
total of 32 studies met inclusion criteria. Among the studies, 78.1% used a cross-
sectional design, 66.7% used both self reports and parent-proxy reports, and 43.3% 
used the Pediatric Quality of Life Inventory (PedsQL) 4.0 instrument. Eleven generic 
and two disease-specific instruments were used. The mean Efficace score for studies 
(N= 30) that measured or reported HRQoL outcomes was 8.9±1.3 (maximum = 11), 
which suggests overall high-quality data. Neither of the disease-specific instru-
ments has been fully validated; however, internal consistency, content validity, and 
hypotheses testing for the PedsQL 3.0 ESRD module were rated as good based on 
the COSMIN checklist. cOnclusiOns: Improved life expectancy in children and 
adolescents with CKD has led to increased concern about their HRQoL; however, 
few studies have used well-validated, disease-specific instruments. Future research 
is warranted to develop and further validate disease-specific HRQoL instruments 
for this population.
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